TherapeuticsMD Inc. (TXMD)

5.09
NASDAQ : Health Technology
Prev Close 5.09
Day Low/High 0.00 / 0.00
52 Wk Low/High 3.50 / 7.66
Avg Volume 2.79M
Exchange NASDAQ
Shares Outstanding 237.88M
Market Cap 1.30B
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Box, Cummins, Verizon: 'Mad Money' Lightning Round

Box, Cummins, Verizon: 'Mad Money' Lightning Round

Jim Cramer is taking a closer look at Box, Cummins, Verizon, TherapeuticsMD, Morgan Stanley, Canopy Growth, Principal Financial and more.

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't Be A Hero: Cramer's 'Mad Money' Recap (Thursday 2/7/19)

Don't get too bearish, says Jim Cramer, but don't break discipline here. This is a perfectly reasonable decline.

First Week Of February 15th Options Trading For TherapeuticsMD (TXMD)

First Week Of February 15th Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options begin trading this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new February 15th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD Announces Participation At 37th Annual J.P. Morgan Healthcare Conference

TherapeuticsMD Announces Participation At 37th Annual J.P. Morgan Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will participate in the 37 th Annual J.

The Charts of TherapeuticsMD Look Bearish to Me

The Charts of TherapeuticsMD Look Bearish to Me

In the daily bar chart of TherapeuticsMD we can see that prices are in a downtrend from June.

Hormel, Medtronic, Cisco and More: 'Mad Money' Lightning Round

Hormel, Medtronic, Cisco and More: 'Mad Money' Lightning Round

Jim Cramer weighs in on Hormel, Medtronic, Cisco and more.

The Fed Is Wrong: Cramer's 'Mad Money' Recap (Thursday 12/20/18)

The Fed Is Wrong: Cramer's 'Mad Money' Recap (Thursday 12/20/18)

Jim Cramer says the market pain will eventually end, once the Fed sees the error of its ways.

Relative Strength Alert For TherapeuticsMD

Relative Strength Alert For TherapeuticsMD

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

TherapeuticsMD Announces Participation In Three Upcoming Investor Conferences

TherapeuticsMD Announces Participation In Three Upcoming Investor Conferences

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will participate in three upcoming healthcare investor conferences.

TherapeuticsMD Announces Third Quarter 2018 Financial Results

TherapeuticsMD Announces Third Quarter 2018 Financial Results

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced its clinical and corporate update for the quarter ended September 30, 2018.

TherapeuticsMD To Report Third Quarter 2018 Financial Results On November 7, 2018

TherapeuticsMD To Report Third Quarter 2018 Financial Results On November 7, 2018

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that it will report its third quarter 2018 financial results on Wednesday, November 7, 2018, after the closing of the U.

TherapeuticsMD Announces FDA Approval Of TX-001HR: BIJUVA™ (Estradiol And Progesterone) Capsules For The Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause

TherapeuticsMD Announces FDA Approval Of TX-001HR: BIJUVA™ (Estradiol And Progesterone) Capsules For The Treatment Of Moderate To Severe Vasomotor Symptoms Due To Menopause

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA™ (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only...

Interesting TXMD Put And Call Options For June 2019

Interesting TXMD Put And Call Options For June 2019

Investors in TherapeuticsMD Inc saw new options become available this week, for the June 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 239 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

JetBlue, BlackRock, United Continental: 'Mad Money' Lightning Round

JetBlue, BlackRock, United Continental: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at JetBlue Airways, BlackRock, United Continental, Kratos Defense & Security, Energy Transfer Partners, TherapeuticsMD.

The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)

The Rally We've Been Waiting For: Cramer's 'Mad Money' Recap (Tuesday 10/16/18)

Panic is not an investment strategy, says Jim Cramer. But when everyone else is panicking, that's when you need to buy.

Dell Technologies, Vail Resorts, Mastercard: 'Mad Money' Lightning Round

Dell Technologies, Vail Resorts, Mastercard: 'Mad Money' Lightning Round

Jim Cramer weighs in on Dell Technologies, Vail Resorts, Mastercard, CyberArk, iRobot, Marriott Vacations, TherapeuticsMD, Edwards Lifesciences.

The China Trade: Cramer's 'Mad Money' Recap (Friday 9/7/18)

The China Trade: Cramer's 'Mad Money' Recap (Friday 9/7/18)

Jim Cramer says the president's predictability on trade makes it clear: Good news for the U.S. economy has become bad news for stocks.

Urban Outfitters, CenturyLink, Avnet: 'Mad Money' Lightning Round

Urban Outfitters, CenturyLink, Avnet: 'Mad Money' Lightning Round

Jim Cramer weighs in on Urban Outfitters, CenturyLink, Avnet, Pitney Bowes, UnitedHealth Group, General Mills, TherapeuticsMD and more.

TherapeuticsMD Announces Multiple Presentations Related To Imvexxy™ And TX-001HR At The 2018 Annual Meeting Of The North American Menopause Society

TherapeuticsMD Announces Multiple Presentations Related To Imvexxy™ And TX-001HR At The 2018 Annual Meeting Of The North American Menopause Society

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the schedule of ten oral presentations and posters at NAMS 2018, the annual meeting of the North American Menopause Society being held in San Diego, California...

TherapeuticsMD Enters Into Label Discussions For TX-001HR

TherapeuticsMD Enters Into Label Discussions For TX-001HR

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the Company has entered into discussions with the U.

First Week Of November 16th Options Trading For TherapeuticsMD (TXMD)

First Week Of November 16th Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TXMD options chain for the new November 16th contracts and identified one put and one call contract of particular interest.

TherapeuticsMD To Present At 2018 Cantor Global Healthcare Conference

TherapeuticsMD To Present At 2018 Cantor Global Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the company will participate in the 2018 Cantor Global Healthcare Conference being held on October 1-3, 2018.

TherapeuticsMD Announces The FDA Has Granted AnnoveraTM Marketing Exclusivity As A New Chemical Entity

TherapeuticsMD Announces The FDA Has Granted AnnoveraTM Marketing Exclusivity As A New Chemical Entity

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that Annovera TM (segesterone acetate and ethinyl estradiol vaginal system) has been granted marketing exclusivity as a new chemical entity (NCE) from the U.

First Week Of January 2021 Options Trading For TherapeuticsMD (TXMD)

First Week Of January 2021 Options Trading For TherapeuticsMD (TXMD)

Investors in TherapeuticsMD Inc saw new options become available this week, for the January 2021 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

TherapeuticsMD Announces Commercial Availability Of Imvexxy™ 4 Mcg

TherapeuticsMD Announces Commercial Availability Of Imvexxy™ 4 Mcg

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced the commercial availability of Imvexxy™ (estradiol vaginal inserts) 4 mcg dose in the United States.

TherapeuticsMD To Present At 13th Annual Wells Fargo Securities Healthcare Conference

TherapeuticsMD To Present At 13th Annual Wells Fargo Securities Healthcare Conference

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women's healthcare company, today announced that the company will present at the 13 th Annual Wells Fargo Securities Healthcare Conference being held on September 5-6, 2018 in Boston.

TherapeuticsMD Announces FDA Approval Of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) For Birth Control

TherapeuticsMD Announces FDA Approval Of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) For Birth Control

TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative women's healthcare company, today announced that the United States (U.

TherapeuticsMD Announces Closing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering Of Common Stock

TherapeuticsMD Announces Closing Of Its Underwritten Public Offering And Concurrent Registered Direct Offering Of Common Stock

TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.

TheStreet Quant Rating: D (Sell)